New Zealand markets closed

Tiziana Life Sciences Ltd (0RP.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3380-0.0080 (-2.31%)
As of 08:00AM CET. Market open.

Tiziana Life Sciences Ltd

14/15 Conduit Street
London W1S 2XJ
United Kingdom

https://www.tizianalifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees9

Key executives

NameTitlePayExercisedYear born
Mr. Gabriele Marco Antonio Cerrone M.B.A.Founder, Executive Chairman & Interim CEO409.9kN/A1972
Dr. Andrea BrancaleScientific FounderN/AN/AN/A
Mr. Richard Clarkson Ph.D.Scientific FounderN/AN/AN/A
Mr. Andrew Westwell Ph.D.Scientific FounderN/AN/AN/A
Ms. Keeren ShahChief Financial OfficerN/AN/A1976
Dr. Matthew W. Davis M.D., R.Ph.COO & Chief Medical OfficerN/AN/AN/A
Dr. William A. Clementi Ph.D., Pharm.D.Chief Development OfficerN/AN/AN/A
Dr. Napoleone Ferrara M.D.Member of Scientific Advisory BoardN/AN/A1958
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Corporate governance

Tiziana Life Sciences Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.